Hydroxychloroquine (HCQ) Sulfate

別名: NSC 4375 中文名稱：硫酸羥氯喹

目錄號(hào)：S4430 Purity: 99.99%

Hydroxychloroquine (HCQ) Sulfate是一種抗瘧疾藥，用于治療系統(tǒng)性紅斑狼瘡，類風(fēng)濕關(guān)節(jié)炎等自身免疫病，炎癥以及皮膚病。它也是autophagy和toll-like receptor (TLR) 7/9的抑制劑。

Hydroxychloroquine (HCQ) Sulfate Chemical Structure

CAS: 747-36-4

規(guī)格	價(jià)格	庫存
10mg	1215.82	現(xiàn)貨
50mg	1764.93	現(xiàn)貨
200mg	3248.32	現(xiàn)貨
1g	7944.3	現(xiàn)貨
更大包裝有超大折扣
400-668-6834 info@selleck.cn

產(chǎn)品質(zhì)控

批次：純度： 99.99%

99.99

Hydroxychloroquine (HCQ) Sulfate相關(guān)產(chǎn)品

相關(guān)產(chǎn)品	Resveratrol Spautin-1 PIK-III DC661 Lys05 Autophinib SMER28 EAD1 Flubendazole EN6 ROC-325 NSC 185058 MPP+ iodide IITZ-01 STF-62247 QX77 CA-5f Lucanthone CA77.1 Daurisoline	點(diǎn)擊展開
相關(guān)化合物庫	激酶抑制劑庫 FDA藥物庫天然產(chǎn)物庫已知活性藥物庫-I 高選擇性抑制劑庫	點(diǎn)擊展開

細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例

細(xì)胞系	實(shí)驗(yàn)類型	給藥濃度	孵育時(shí)間	活性描述	文獻(xiàn)信息
Antiproliferative assay	A549 cells	25 ug/ml	20 hrs	Antiproliferative activity in human A549 cells at 25 ug/ml up to 20 hrs by xCELLigence RTCA SP based cellular impedance analysis	28570977
Antiproliferative assay	A549 cells	25 ug/ml	60 hrs	Antiproliferative activity in human A549 cells at 25 ug/ml after 60 hrs by xCELLigence RTCA SP based cellular impedance analysis	28570977
Autophagy assay	NCI-H3122 cells	25 to 50 uM	6 hrs	Inhibition of autophagy in human NCI-H3122 cells assessed as increase in punctate LC3 expression at 25 to 50 uM after 6 hrs by fluorescence microscopic analysis	25699157
Apoptosis assay	H460 cells	25 to 75 uM	24 hrs	Induction of apoptosis in human H460 cells at 25 to 75 uM after 24 hrs by annexin-V staining-based flow cytometry	25699157
Antiviral assay	Vero E6 cells		48 h	IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells)., IC50 = 0.67608 μM.	32353859
Antiproliferative assay	BxPC3 cells		72 hrs	Antiproliferative activity against human BxPC3 cells after 72 hrs by SRB method, IC50 = 33 μM.	25699157
Autophagy assay	H460 cells		24 hrs	Inhibition of autophagy in human H460 cells assessed as increase in LC3-2 level at IC50 after 24 hrs by immunoblot analysis	25699157
Antiviral assay	Vero E6 cells		2 days	Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days, EC50 = 4.17 μM.	ChEMBL
Antiviral assay	Vero E6 cells		3 days	IC50 determination at MOI 0.004 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells, IC50 = 9.21 μM.	ChEMBL
Antiviral assay	Vero E6 cells		3 days	IC50 determination at MOI 0.01 using CellTiter- Glo (CTG) assay, performed 3 days post-infection in SARS-CoV-2 infected Vero E6 cells, IC50 = 11.17 μM.	ChEMBL
Antiviral assay	Vero E6 cells		2 days	Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days, EC90 = 25.49 μM.	ChEMBL
Function assay	HEK-Blue cells			Antagonist activity at human TLR9 expressed in HEK-Blue cells assessed as reduction in CpGB-induced NF-kappaB levels after 24 hrs by spectrophotometric analysis, IC50 = 0.11 μM.	30292896
Function assay	HEK-Blue cells			Antagonist activity at human TLR7 expressed in HEK-Blue cells assessed as reduction in CL264-induced NF-kappaB levels after 24 hrs by spectrophotometric analysis, IC50 = 0.8 μM.	30292896
Function assay	HEK293 cells			hERG binding assays: Displacement of [3H]-Dofetilide (5 nM final) from hERG membranes obtained from HEK293 cells, Ki = 2.51189 μM.	32353859
Antiviral assay	Vero E6 cells			IC90 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line by measuring infectious viral titer of supernatent from compound-treated Vero E6 cells by Median Tissue Culture Infectious Dose (TCID)50 by the method of Reed and Muench, IC90 = 5.78 μM.	32353859
qHTS assay	A673 cells			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
qHTS assay	BT-37 cells			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
qHTS assay	SK-N-MC cells			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
qHTS assay	NB-EBc1 cells			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
qHTS assay	LAN-5 cells			qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù)

生物活性

產(chǎn)品描述

靶點(diǎn)

TLR9 ^[5]

Autophagy ^[1]

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試驗(yàn)信息 (data from https://clinicaltrials.gov, updated on 2024-05-22)
NCT06408298	Not yet recruiting	Resectable Localized Prostate Cancer	Lionel.D.Lewis MD\|Dartmouth Cancer Center\|Dartmouth-Hitchcock Medical Center	June 2024	Early Phase 1
NCT05841758	Not yet recruiting	Sarcoidosis Pulmonary	Hospices Civils de Lyon	April 1 2024	Phase 4
NCT04731051	Withdrawn	2019 Novel Coronavirus	King Hussein Cancer Center\|Amman Pharmaceutical Industries (API)\|Sana Pharmaceutical Industry\|ACDIMA Biocenter	October 2022	Phase 1\|Phase 2
NCT05733897	Recruiting	Nonalcoholic Steatohepatitis	National Taiwan University Hospital\|National Taiwan University	June 10 2022	--
NCT05237843	Unknown status	Recurrent Pregnancy Loss	Ain Shams University	March 1 2022	Phase 1

參考文獻(xiàn)
[1] Ramser B, et al.J Invest Dermatol, 2009,129(10):2419-26. [2] Lee HO, et al. PLoS One. 2015, 10(7): e0131464. [3] Bourke L, et al. PLoS One. 2015, 10(12):e0143771. [4] Marta Mosca, et al. 2013 ACR/ARHP Annual Meeting. [5] Lamphier M, et al. Mol Pharmacol. 2014, 85(3):429-440. + 展開

參考文獻(xiàn)

[1] Ramser B, et al.J Invest Dermatol, 2009,129(10):2419-26.
[2] Lee HO, et al. PLoS One. 2015, 10(7): e0131464.
[3] Bourke L, et al. PLoS One. 2015, 10(12):e0143771.

[4] Marta Mosca, et al. 2013 ACR/ARHP Annual Meeting.
[5] Lamphier M, et al. Mol Pharmacol. 2014, 85(3):429-440.

+ 展開